May 13, 2014 / 1:00 AM / in 3 years

Pfizer keen to engage with AstraZeneca board

A man walks past Pfizer's world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly

LONDON (Reuters) - U.S. drugmaker Pfizer kept up the pressure on bid target AstraZeneca on Tuesday, saying its offer represented compelling value for a company which would otherwise face challenges as a standalone firm.

Pfizer released a statement to set out its case for the deal, just hours before its chief executive appears in front of a British parliamentary committee to explain why he wants to acquire Britain’s second largest drugmaker.

AstraZeneca has rejected a $106 billion bid from Pfizer but the U.S. group is widely expected to return with a higher offer later this week.

Reporting by Kate Holton; Editing by Neil Maidment

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below